Recent Updates
Recently added Catalysts
FENC Positive Sentiment

FENNEC PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCE

Thursday, November 14, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Fennec Pharmaceuticals Inc. will participate in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024. The event will take place at the Sheraton New York Times Square Hotel, where the company's management will hold one-on-one meetings with investors. Fennec focuses on reducing platinum-induced ototoxicity in pediatric patients with its product PEDMARK, which has received several regulatory approvals.
Price reaction · baseline $4.34 (2024-11-14T16:34:00.000Z) · hit during market hours · clean, no other FENC news in the window
day 0 close · peak
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Fennec Pharmaceuticals is participating in a notable investor conference.
  • Management will be available for one-on-one meetings, enhancing investor engagement.
  • The company has received multiple regulatory approvals for its product PEDMARK.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
22.8%
average across 3 past catalysts
Lead asset
ADH-1
Phase 2 · Neoplasms

Full Press Release Details

Research Triangle Park, NC, November 13, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company’s management will be available for one-on-one meetings throughout the event.
Conference Details:
Event: 15th Annual Craig-Hallum Alpha Select Conference Date: November 19, 2024
Location: Sheraton New York Times Square Hotel, New York City
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK Ò to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI Ò . PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com .
For further information, please contact:

Frequently Asked Questions

When is the Craig-Hallum Alpha Select Conference?

The conference is scheduled for November 19, 2024.

Where will the conference be held?

It will take place at the Sheraton New York Times Square Hotel.

What is the focus of Fennec Pharmaceuticals?

The company focuses on reducing platinum-induced ototoxicity in pediatric patients.

What approvals has PEDMARK received?

PEDMARK received FDA approval in September 2022 and European approval in June 2023.

ShareAdd on Google
Tags: FENC Viatris Investor Conferences Healthcare investor conference Craig-Hallum PEDMARK FDA approval
Last updated: Nov 14, 2024

Biotech snapshot

Cash runway
$41M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ADH-1Phase 2
Neoplasms →

Catalyst track record

+70%
best trade around FENC's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for FENC.

See every catalyst's timing & PoA →